Piramal Pharma Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,140Cr
- −2.9% YoY
- +4.7% QoQ
- Net profit
- −₹136Cr
- Q3 FY25: ₹4 Cr
- Margin
- 9.15%
- −6.2 pp YoY
- +1.4 pp QoQ
Guidance rank: #42 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Q4 is expected to show sequential revenue growth compared to Q3, but no year-on-year Q4 versus Q4 growth due to a strong large order last year. FY '26 is muted due to inventory destocking, slower U.S.
From Piramal Pharma Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Q4 is expected to show sequential revenue growth compared to Q3, but no year-on-year Q4 versus Q4 growth due to a strong large order last year.
- CDMO business (excluding inventory destocking) is growing in low single digits, with expectations for continued growth driven by improved biotech funding and new client additions.
- Overseas CDMO facilities with high gross margin profiles are anticipated to enhance margins as capacity utilization improves.
- The consumer products business, now breakeven, is expected to expand margins and grow further.
- The Kenalog acquisition (annualized sales $30-$40 million) adds a stable, near-to-medium-term contributor, fitting strategically with existing portfolio and sales capabilities.
2 more points from Piramal Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Average CAPEX spend is between $70 million to $100 million annually.
- Higher CAPEX expected in the near term due to major expansions at Lexington and Riverview facilities.
- Lexington expansion is underway, with commissioning expected by end of Calendar Year 2027.
- Riverview facility's linker payload expansion is nearly ready and expected to come online this quarter.
- Investments are aligned with long-term plans and payback metrics for CDMO and Complex Hospital Generics (CHG) businesses.
- Consumer products business is self-funding and does not require external capital infusion.
2 more points from Piramal Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has a large Phase-3 pipeline with over 30 products, with programs primarily in oncology, metabolic diseases, and rare diseases.
- Order booking saw an improvement in Q3 FY '26, serving as a leading indicator of client ability to fund and spend on CDMO services.
- Since October 2025, there has been a significant increase in RFPs (Request for Proposals), especially for U.S. facilities, indicating growing demand.
- Typical lead time from proposal to client decision is around 180 days.
- There is cautious optimism about translating these RFPs into confirmed orders over the next 180 days.
- The impact of inventory destocking on order volumes is expected to normalize, with underlying portfolio growth in low single digits excluding destocking effects.
2 more points from Piramal Pharma Ltd's call on order book
Create a free account to keep reading this call
Piramal Pharma Ltd — Quarterly revenue & net profit
Piramal Pharma Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,140 | 2,204 | -2.9% | 2,044 | +4.7% |
| Operating profit (EBITDA) | 196 | 338 | -42% | 159 | +23.3% |
| Operating margin | 9.15% | 15.32% | -6.2 pp | 7.76% | +1.4 pp |
| Profit before tax | -94 | 67 | -240.5% | -46 | — |
| Net profit (PAT) | -136 | 4 | -3800.8% | -99 | — |
| EPS (₹) | -1.02 | 0.03 | -3500% | -0.75 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Piramal Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Piramal Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Piramal Pharma Ltd Q3 FY26 results?
Q4 is expected to show sequential revenue growth compared to Q3, but no year-on-year Q4 versus Q4 growth due to a strong large order last year. FY '26 is muted due to inventory destocking, slower U.S.
What is Piramal Pharma Ltd share price analysis?
Piramal Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹27,530 Cr. Investors should review the full earnings analysis for detailed insights.
Is Piramal Pharma Ltd planning capital expenditure?
Average CAPEX spend is between $70 million to $100 million annually.
Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
